Breaking news on pharma_industry
Pharmaceutical Legislation Changes In Europe - EMA and Member States Prepare published
Fri, 03 Feb 2012 10:00:00 PST
Preparations are underway at the European Medicines Agency together with European Member States and the European Commission, for the introduction of the new pharmacovigilance legislation in July this year. The new legislation will represent the biggest change to the legal framework since The Agency was founded in 1995...
Open Innovation Possibilities To Be Explored By Fleming Europe In Amsterdam, 26 - 27 April 2012 published
Thu, 02 Feb 2012 01:00:00 PST
Major blockbuster drugs are facing the end of their era and big pharma companies are bracing for the effect in hopes that they will find a solution for their dwindling pipelines. Thus new opportunities and challenges are rising in the practice of open innovation and Fleming Europe will be there to explore them...
2nd Annual Achieving Clinical & Regulatory Excellence In Turkey, The Middle East & North Africa Conference, 11-14 June 2012, Istanbul, Turkey published
Wed, 01 Feb 2012 00:00:00 PST
NextLevel Pharma's "Advancing clinical research in Turkey, the Middle East and North Africa" conference will bring together the local regulators and ethics committees, alongside experienced investigators and study personnel, as well as clinical trial experts from pharma and CROs...
Pharmaceutical And Medical Device Market Access In Key Asian Markets Conference, 3-4 May 2012, Bangkok, Thailand published
Tue, 31 Jan 2012 00:00:00 PST
Asian markets are increasingly the focus of pharmaceutical companies who are looking for new market opportunities beyond the traditional "rich-world" countries who are facing economic stagnation...
Best Practices In Implementing Green Pharmaceutical Manufacturing Conference, 29-30 March 2012, Vienna, Austria published
Mon, 30 Jan 2012 00:00:00 PST
This unique and timely event will highlight how different frameworks and initiatives have succeeded in developing an efficient, environmentally friendly manufacturing process in the pharmaceutical industry...
Shortages Of Anti-Infective Drugs Pose Threat To Public Health And Patient Care published
Mon, 23 Jan 2012 01:00:00 PST
Shortages of key drugs used to fight infections represent a public health emergency and can put patients at risk, according to a review published in Clinical Infectious Diseases and available online*...
2nd Annual World Orphan Drug Congress USA, April 10-13 2012 published
Fri, 20 Jan 2012 05:00:00 PST
Orphan drug development has become more feasible than in previous years but we've barely scratched the surface: only 367 approved orphan drugs out of 6,800 rare diseases. We need to keep the momentum going. Come April 10-13, over 300 key decision makers from orphan drug manufacturers, patient groups, payers and regulators will gather in DC at the 2nd annual World Orphan Drug Congress USA...
Seminar On Monitoring And Validating Pharmaceutical Water Systems, 22-23 February 2012, San Francisco, CA published
Fri, 20 Jan 2012 01:00:00 PST
ComplianceOnline, the leading governance, risk and compliance advisory network with over 500 experts in various regulatory subjects, today announced a seminar on The A to Z's of Microbial Control, Monitoring and Validation of Pharmaceutical Water Systems. The two day long, in-person seminar, led by well known water systems expert T.C...
Oxygen And Light Utilized In The Synthesis Of Anti-Malaria Drug published
Thu, 19 Jan 2012 00:00:00 PST
The most effective anti-malaria drug can now be produced inexpensively and in large quantities. This means that it will be possible to provide medication for the 225 million malaria patients in developing countries at an affordable price...
Clinical Outsourcing World Europe 2012, 7-8 February, Earls Court Conference Centre - London published
Wed, 18 Jan 2012 06:00:00 PST
Driving development through strategic outsourcingRegister NOW for the Clinical Outsourcing World conference to hear from the industry's BEST Outsourcing professionals including representatives from: GSK, Pfizer, AstraZeneca, Eli Lilly, Novartis, Almirall, Merck Research Laboratories and many more! Pharma & Biotech delegates- register NOW for only £250+vat! Please note this ...
Fake Antimalarial Medications Undermine Africa Malaria Drive published
Tue, 17 Jan 2012 15:00:00 PST
Fraudulent and substandard antimalarial drugs could be wrecking the chances of winning the war against malaria in Africa, researchers from the Wellcome Trust-Mahosot Hospital-Oxford University Tropical Medicine Research Collaboration reported in the Malaria Journal...
Blocking Cell-To-Cell Communication May Prevent Liver Damage And Improve Drug Safety published
Tue, 17 Jan 2012 00:00:00 PST
Massachusetts General Hospital (MGH) investigators have developed a novel strategy to protect the liver from drug-induced injury and improve associated drug safety...
Advances And Progress In Drug Design - Discover The Latest Developments 20-21 February 2012, Copthorne Tara Hotel, London published
Mon, 16 Jan 2012 00:00:00 PST
The number of pharmaceutical products entering the market has declined in the last decade. With the economic downturn and increasing threat from generic companies, pharmaceutical companies have never been under greater pressure to develop new innovative drugs...
Understand The Strategies And Developments In Pharmaceutical Parallel Trade, 6-7 February 2012 At The Copthorne Tara Hotel In London published
Sun, 15 Jan 2012 00:00:00 PST
SMi is proud to present their 6th annual Pharmaceutical Parallel Trade Conference, taking place on 6th & 7th February 2012 at the Copthorne Tara Hotel in London. This year's event will bring together expert speakers from different sectors within the industry, each with differing opinions and perspectives to offer...
Chemical Reaction Devized That Holds Promise For New Drug Development published
Sat, 14 Jan 2012 00:00:00 PST
A team of researchers at the California Institute of Technology (Caltech) has devised a new method for making complex molecules...
Major Advance In Understanding The Regulation Of An Important Cancer Target published
Thu, 12 Jan 2012 00:00:00 PST
Scientists at the University of Leicester have opened up a whole new approach to the therapeutic intervention for a family of anti-cancer drug targets, thanks to a completely new and unexpected finding...
Novartis' Troubles With Packaging Continue published
Mon, 09 Jan 2012 12:00:00 PST
Novartis Consumer Health announced earlier today a recall on certain OTC medicines that were badly packaged and might have broken or chipped pills, as well as incorrect product mixed into bottles of pills. Rather worrying for consumers with risks of possible wrong or overdoses of their medicine...
Novartis Recalls OTC Products Excedrin And NoDoz published
Mon, 09 Jan 2012 09:00:00 PST
Complaints of chipped and broken pills as well as inconsistent packaging have promoted Novartis Consumer Health Inc. (NCH) to recall certain lots of its products. Whilst there have been no reports of adverse effects to patients so far, Novartis has also warned of possible mixing of product. They have asked consumers to dispose of the product or return unused bottles...
New Drug Screening Identifies Chemical Agents With Potent Anti-Cancer Activity published
Sun, 08 Jan 2012 00:00:00 PST
Drugs already approved for clinical use across a variety of therapeutic categories can be screened to identify effective agents for thyroid cancer according to a recent study accepted for publication in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM). These findings could rapidly be implemented into a clinical trial to test how effective the treatment would be...
The Importance Of Compliance In Your KOL Interactions published
Fri, 06 Jan 2012 10:00:00 PST
With the recent changes to regulations about interactions with external stakeholders, it can be hard to keep up to date. Eyeforpharma spoke to Julian Jenkins, Head of Global Medical Affairs at Ferring Pharmaceuticals about how to work compliantly under the changing regulatory environment...
Discovery Of One Of The Most Porous Materials To Date Will Improve Control In Drug Delivery published
Thu, 05 Jan 2012 00:00:00 PST
The delivery of pharmaceuticals into the human body or the storage of voluminous quantities of gas molecules could now be better controlled, thanks to a study by University of Pittsburgh researchers. In a paper published online in Nature Communications, a team of chemists and colleagues from Pitt's Kenneth P...
ONSOLIS To Benefit From Approval Of Class-Wide REMS For All Transmucosal Fentanyl Products published
Tue, 03 Jan 2012 01:00:00 PST
BioDelivery Sciences International, Inc. (Nasdaq: BDSI) responded to the approval and announcement by the U.S. Food and Drug Administration (FDA) that a Risk Evaluation Mitigation Strategy (REMS) covering all transmucosal fentanyl products has been approved...
FDA Approves Shared REMS (Risk Evaluation And Mitigation Strategy) Program For All TIRF (Transmucosal Immediate Release Fentanyl) Pain Treatments published
Tue, 03 Jan 2012 01:00:00 PST
ProStrakan, Inc., a subsidiary of Kyowa Hakko Kirin Co. Ltd. (KHK), and an international specialty pharmaceutical company, announces that the U.S. Food and Drug Administration (FDA) has approved the TIRF (Transmucosal Immediate Release Fentanyl) REMS (Risk Evaluation and Mitigation Strategy) Access program...
Marinus Pharmaceuticals Experimental Epilepsy Treatment Shows Promise In Open-Label Extension Study published
Sun, 01 Jan 2012 01:00:00 PST
Marinus Pharmaceuticals, Inc., a specialty pharmaceutical company, announced that its neurosteroid ganaxolone which is currently under study for the treatment of partial onset seizures (POS), reported positive data in the open-label extension follow up to the company's Phase 2 clinical trial. The data reflects the replication of the effects seen in the double-blind study...
VIVUS Announces Date Of FDA Advisory Committee Review Of Qnexa For The Treatment Of Obesity published
Sun, 01 Jan 2012 01:00:00 PST
VIVUS, Inc. (NASDAQ: VVUS) announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) is scheduled to review the Company's New Drug Application (NDA) for Qnexa for the treatment of obesity on February 22, 2012. VIVUS resubmitted the NDA on October 17, 2011 seeking approval to market Qnexa in the United States...
)
|
|
